Crispr Therapeutics And Sirius Therapeutics Announce Multi-Target Collaboration To Develop Novel Sirna Therapies
Reuters
20 May
CRISPR Therapeutics AG:: *CRISPR THERAPEUTICS AND SIRIUS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO DEVELOP NOVEL SIRNA THERAPIES *CRISPR THERAPEUTICS AG: WILL MAKE AN UPFRONT PAYMENT OF $25 MILLION IN CASH AND $70 MILLION IN EQUITY TO SIRIUS THERAPEUTICS *CRISPR THERAPEUTICS AG: ALSO HAS RIGHTS TO EXCLUSIVELY LICENSE UP TO TWO ADDITIONAL SIRNA PROGRAMS *CRISPR THERAPEUTICS AG - SRSD107 SHOWS >93% FXI REDUCTION IN PHASE 1 TRIAL
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.